94 results
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
9 May 24
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
4:10pm
IVT injection in the physician’s office, deliver long-term efficacy, reduce the burden of frequent anti-vascular endothelial growth factor (VEGF
424B3
ADVM
Adverum Biotechnologies Inc
20 Mar 24
Prospectus supplement
5:04pm
, in-office intravitreal (“IVT”) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated
8-K
EX-99.1
qc0yaiusj36kvbd
18 Mar 24
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
4:08pm
8-K
EX-99.1
s5qkt93xu
8 Feb 24
Regulation FD Disclosure
8:45am
8-K
EX-99.1
zp3ao xvs5
9 Nov 23
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
4:07pm
8-K
EX-99.1
kr8pi 2493awoe
10 Aug 23
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
4:09pm
424B5
3w1kwbt
11 May 23
Prospectus supplement for primary offering
4:43pm
8-K
EX-99.1
fd9s80t9nm6lq94w
11 May 23
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
4:10pm
PRE 14A
xbx3utn ez9derw7
14 Apr 23
Preliminary proxy
6:03am